ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Selective Lipoprotein Removal Enables High-Purity EV Isolation from Plasma via Aptamer-Based Mesh Filtration.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lipoproteins pose a major challenge to plasma extracellular vesicle (EV) isolation due to their abundance and physical similarity to EVs. Here, we present ApoFilter, a rapid and selective aptamer-based mesh-filtration platform that efficiently depletes ApoA1- and ApoB100-positive lipoproteins. High-affinity aptamers immobilized onto nylon mesh layers capture targeted lipoproteins in a spin-column format, enabling rapid (1 min) separation under gravity-driven flow. ApoFilter removed >99% of targeted lipoproteins (HDL and (V)LDL) from purified and plasma samples, with negligible capture of non-target components and no compromise to EV integrity. When integrated with conventional EV isolation methods-including ultracentrifugation (UC), size-exclusion chromatography (SEC), and ExoTFF-ApoFilter consistently eliminated lipoprotein contaminants across all workflows. This simple and rapid system addresses a key bottleneck in EV research, enabling the collection of ultrapure EVs suitable for downstream molecular analyses and translational applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.